Machining antibodies at IPI
Very little these days escapes the reach of machine learning (ML) and, more broadly, artificial…
Axon Guidance: Explained
In the late 19th century, neuroscientist Santiago Ramón y Cajal peered through a microscope at…
IPI receives grant from Chan Zuckerberg Initiative to develop next-generation protein tools for neuroscience research
Funding supports creation and open distribution of critical research tools to accelerate neuroscience discoveries Boston,…
IPI targets neurexin with upcoming antibody suite
Snynaptic function involves the interactions of hundreds, maybe thousands, of different proteins. A particular family,…
Epitope tag antibodies, plasmids and data transparency: A Q&A with Mike Walden
In 2024, the Institute for Protein Innovation (IPI) released a set of antibodies targeting nine…
Year in review: Looking back on 2024
It’s been a whirlwind year here at IPI, from antibody releases to workshops and lab…
Michael Walden bridges two worlds as IPI’s commercial director
Driving commercial development at a nonprofit institution is a challenge. The business models are complex…
Glypicans: Explained
Hundreds of millions of years before humans evolved, a family of proteins came to be…
Deborah Moshinsky’s enterprising behind-the-scenes efforts ensure antibody quality
Deborah “Deb” Moshinsky is the type of process-motivated scientist that all labs require — but…
IPI’s Antibodies Roadshow fosters neuroscience collaborations
The Institute for Protein Innovation (IPI) kicked off its inaugural “Antibodies Roadshow” on Saturday, October…
Community validation effort draws inspiration from famed HLDA workshops
The Institute for Protein Innovation (IPI), typically quiet on a Sunday afternoon, buzzed with excitement…
IPI plasmids offer a build-your-own-antibody tool to protein researchers
True to its mission to accelerate research through the advancement of protein science, the Institute…